# Avelumab Program Rollover Study

Source: https://onco.cc/trials/nct03815643/  
OnCo record `nct03815643` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Avelumab in advanced solid tumours, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.

## Summary

Avelumab Program Rollover Study is a phase 3 interventional study registered as NCT03815643 by EMD Serono Research & Development Institute, Inc., with 205 participants enrolled, started 2019-03-22 and due to reach its primary completion in 2026-08-21. Interventions recorded: Avelumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03815643
- Phase: 3
- Setting: An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Enrolled: 205

## Sources

- ClinicalTrials.gov NCT03815643: https://clinicaltrials.gov/study/NCT03815643

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Avelumab](https://onco.cc/drugs/avelumab/)
- companies: [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/)

---
JSON: https://onco.cc/api/v1/entities/nct03815643.json